Expanded access program for cannabidivarin in autism spectrum disorders

Trial Profile

Expanded access program for cannabidivarin in autism spectrum disorders

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 May 2017

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Autistic disorder
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 17 May 2017 New trial record
    • 09 May 2017 According to a GW Pharmaceuticals media release, the US FDA has granted IND approval for this expanded access program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top